The recording of adverse events from psychological treatments in clinical trials: evidence from a review of NIHR-funded trials

被引:114
|
作者
Duggan, Conor [1 ,2 ]
Parry, Glenys [3 ]
McMurran, Mary [1 ]
Davidson, Kate [4 ]
Dennis, Jane [5 ]
机构
[1] Univ Nottingham, Inst Mental Hlth, Nottingham NG7 2TU, England
[2] Head Res & Dev, Borehamwood WD6 JN, Herts, England
[3] Univ Sheffield, Sch Hlth & Related Res, Ctr Psychol Serv Res, Sheffield S1 4DA, S Yorkshire, England
[4] Univ Glasgow, Gartnavel Royal Hosp, Coll Med Vet & Life Sci, Inst Hlth & Wellbeing, Glasgow G12 0XH, Lanark, Scotland
[5] Social Well Fare Grp, Bristol BS6 7DB, Avon, England
来源
TRIALS | 2014年 / 15卷
基金
美国国家卫生研究院;
关键词
Harm; Adverse events; Psychological interventions; Clinical trials; RANDOMIZED-TRIALS; PSYCHOTHERAPY; EXTENSION; THERAPY; SAFETY; HARMS;
D O I
10.1186/1745-6215-15-335
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: There is a concern in the literature that harm from interventions is insufficiently documented in clinical trials in general, and in those assessing psychological treatments in particular. A recent decision by a trial steering committee to stop recruitment into a randomized controlled trial (RCT) of a psychological intervention for personality disorder led to an investigation of the recording of harm in trials funded by the National Institute for Health Research (NIHR). Methods: The protocols and final reports of all 82 NIHR trials funded between 1995 and 2013 were examined for the reporting of adverse events. These were subdivided by category of intervention. Results: None of the psychological intervention trials mentioned the occurrence of an adverse event in their final report. Trials of drug treatments were more likely to mention adverse events in their protocols compared with those using psychological treatments. When adverse events were mentioned, the protocols of psychological interventions relied heavily on severe adverse events guidelines from the National Research Ethics Service (NRES), which were developed for drug rather than psychological interventions and so may not be appropriate for the latter. Conclusions: This survey supported the belief that the reporting of adverse events in psychological treatments is weak and the criteria used may not be appropriate. Recommendations are made as to how current practice might be improved.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] The recording of adverse events from psychological treatments in clinical trials: evidence from a review of NIHR-funded trials
    Conor Duggan
    Glenys Parry
    Mary McMurran
    Kate Davidson
    Jane Dennis
    Trials, 15
  • [2] Measuring and reporting adverse events in clinical trials of psychological treatments for chronic pain
    Palermo, Tonya M.
    Slack, Katherine
    Loren, Dorothy
    Eccleston, Christopher
    Jamison, Robert N.
    PAIN, 2020, 161 (04) : 713 - 717
  • [4] Reduction of coronary events: Evidence from clinical trials
    Gotto, AM
    CURRENT OPINION IN LIPIDOLOGY, 1995, 6 (06) : 345 - 347
  • [5] NIHR clinical trials fellowship: reflections from a fellow and a mentor
    Whitehead, Phillip
    Sprange, Kirsty
    Montgomery, Alan
    TRIALS, 2017, 18
  • [6] Challenges in Coding Adverse Events in Clinical Trials: A Systematic Review
    Schroll, Jeppe Bennekou
    Maund, Emma
    Gotzsche, Peter C.
    PLOS ONE, 2012, 7 (07):
  • [7] Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials
    Mancia, Giuseppe
    Schumacher, Helmut
    PATIENT PREFERENCE AND ADHERENCE, 2012, 6 : 1 - 9
  • [8] PUBLICATION IMPACT FROM NIMH FUNDED CLINICAL TRIALS
    Gogtay, Nitin
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S313 - S313
  • [9] Efficient methods for signal detection from correlated adverse events in clinical trials
    Diao, Guoqing
    Liu, Guanghan F.
    Zeng, Donglin
    Wang, William
    Tan, Xianming
    Heyse, Joseph F.
    Ibrahim, Joseph G.
    BIOMETRICS, 2019, 75 (03) : 1000 - 1008
  • [10] Pitfalls in meta-analyses on adverse events reported from clinical trials
    Huang, Han-Yao
    Andrews, Elizabeth
    Jones, Judith
    Skovron, Mary Lou
    Tilson, Hugh
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (10) : 1014 - 1020